Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al., No. 1:25-cv-10251 [3]. - Investors have until February 9, 2026, to request to be appointed to lead the case [3]. Group 2: Company Performance and Allegations - Integer designs and manufactures cardiac rhythm management and cardiovascular products, including electrophysiology devices [4]. - The company allegedly overstated demand for its electrophysiology devices while public assurances contradicted the actual decline in demand and revenue [5]. - On October 23, 2025, Integer lowered its 2025 sales guidance to between $1.840 billion and $1.854 billion, down from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations [6]. - Integer also projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026, admitting that two of its EP devices had slower than expected adoption [6]. Group 3: Stock Impact - Following the announcement of lowered sales guidance, Integer's stock price dropped by $35.22 per share, a decline of over 32%, from $109.11 per share on October 22, 2025, to $73.89 per share on October 23, 2025 [6].

Core Viewpoint - A class action securities lawsuit has been filed against Integer Holdings Corporation, alleging securities fraud that affected investors between July 25, 2024, and October 22, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Integer Holdings Corporation materially overstated its competitive position in the electrophysiology manufacturing market [2]. - It is alleged that despite claims of strong visibility into customer demand, the company was experiencing a sustained deterioration in sales related to two of its electrophysiology devices [2]. - The complaint further asserts that Integer mischaracterized its electrophysiology devices as a long-term growth driver for its cardio & vascular segment, leading to materially false and misleading statements about the company's business and prospects [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the relevant time frame have until February 9, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - Rosen Law Firm is reminding purchasers of Integer Holdings Corporation common stock about the upcoming lead plaintiff deadline for a class action lawsuit related to alleged misleading statements made by the company during the specified class period [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from July 25, 2024, to October 22, 2025, inclusive [1]. - Investors who purchased Integer common stock during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by February 9, 2026 [3]. Group 2: Allegations Against Integer Holdings - The lawsuit alleges that Integer made materially false and misleading statements regarding its competitive position in the electrophysiology manufacturing market [5]. - It is claimed that Integer overstated its visibility into customer demand while experiencing a deterioration in sales for two of its electrophysiology devices [5]. - The company mischaracterized its electrophysiology devices as long-term growth drivers for its cardio and vascular segment, leading to misleading positive statements about its business and operations [5].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al., No. 1:25-cv-10251 [3]. - Investors have until February 9, 2026, to request to lead the case [3]. Group 2: Company Performance and Allegations - Integer designs and manufactures cardiac rhythm management and cardiovascular products, including electrophysiology devices [4]. - The company allegedly overstated demand for its electrophysiology devices while public assurances contradicted the actual decline in demand and revenue [5]. - On October 23, 2025, Integer lowered its 2025 sales guidance to between $1.840 billion and $1.854 billion, down from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations [6]. Group 3: Stock Impact - Following the announcement of lowered sales guidance, Integer's stock price dropped by $35.22 per share, a decline of over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [6].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation for allegedly misleading investors regarding its competitive position and sales performance in the EP manufacturing market [2][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Integer common stock between July 25, 2024, and October 22, 2025, with a deadline of February 9, 2026, for investors to apply as lead plaintiffs [2]. - Allegations include that the company overstated its competitive position, misrepresented customer demand visibility, and mischaracterized its EP devices as growth drivers, leading to materially false and misleading statements about its business [3]. Group 2: Next Steps for Investors - Investors who suffered losses and wish to learn more about the claims or have questions can contact the law firm directly without any cost or obligation [4].

Core Viewpoint - Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by officers and directors of Integer Holdings Corporation (NYSE: ITGR) related to shareholder interests [1]. Group 1: Allegations of Misrepresentation - A federal securities lawsuit claims that insiders at Integer misrepresented the company's competitive position in the expanding EP manufacturing market [2]. - The lawsuit alleges that Integer overstated its visibility into customer demand while actually experiencing a decline in sales for two of its EP devices [2]. - Integer is accused of mischaracterizing its EP devices as a long-term growth driver for its C&V segment, leading to materially false and misleading statements about the company's business and prospects [2].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation for allegedly making misleading statements and failing to disclose material adverse facts regarding its business performance during the specified class period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Integer securities from July 25, 2024, to October 22, 2025 [1][2]. - Investors have until February 9, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations Against the Company - The complaint alleges that Integer overstated its competitive position and did not adequately disclose sales deterioration in its electrophysiology devices [3]. - The lawsuit claims that the company mischaracterized its growth drivers [3]. - The truth about the company's performance began to emerge on October 23, 2025, when it reduced its sales guidance, leading to a stock price decline of $35.22 per share, a drop of over 32% in one trading day [3].

Core Viewpoint - Integer Holdings Corporation (NYSE: ITGR) is facing allegations of issuing materially false and misleading statements regarding its competitive position and sales performance in the electrophysiology manufacturing market during the class period from July 25, 2024, to October 22, 2025 [3]. Group 1: Allegations - The complaint alleges that Integer overstated its competitive position within the growing electrophysiology manufacturing market [3]. - Despite claims of strong visibility into customer demand, Integer was experiencing a sustained deterioration in sales related to two of its electrophysiology devices [3]. - Integer mischaracterized its electrophysiology devices as a long-term growth driver for the Company's cardio & vascular segment [3]. - As a result of these issues, the defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading [3]. Group 2: Class Action Details - Shareholders who purchased shares of ITGR during the specified class period are encouraged to contact the Gross Law Firm regarding possible lead plaintiff appointment [1]. - The deadline for shareholders to register for the class action is February 9, 2026 [4]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive status updates throughout the lifecycle of the case [4].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [4][5]. Stock Price Decline - On October 23, 2025, Integer revised its 2025 sales guidance down to between $1.840 billion and $1.854 billion, significantly below analysts' expectations. The company also projected a net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026. This announcement led to a stock price drop of $35.22 per share, or over 32%, from $109.11 to $73.89 [6].

~ Attendees Invited to Visit Integer at Booth #115 ~PLANO, Texas, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, will join global medtech leaders and innovators in exhibiting at the North American Neuromodulation Society (NANS) Annual Meeting in Las Vegas from Jan. 22 – 25, 2026. At booth #115, Integer will spotlight its latest advancements in neuromodulation and next-gen ...